Hematologia e Hemoterapia

Vaccination in Multiple Myeloma: Challenges and Strategies.

European journal of haematology. 2025 Oct; 115(Oct):334-343. doi: 10.1111/ejh.70013. pii: .

Efficacy of CD19 CAR T-cell therapy for patients with B-cell acute lymphoblastic leukemia relapsed after allogeneic transplantation.

Leukemia & lymphoma. 2026 Jan; 1-4. doi: 10.1080/10428194.2026.2619496. pii: .

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

The New England journal of medicine. 2026 Feb; 394(Feb):739-752. doi: 10.1056/NEJMoa2514663. pii: .

CAR T Cell Toxicities and Emerging Treatment Strategies.

Annual review of medicine. 2026 Jan; 77(Jan):219-237. doi: 10.1146/annurev-med-050224-120336. pii: .

Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard?

Oncology (Williston Park, N.Y.). 2026 Feb; 40(Feb):34-42. doi: 10.46883/2026.25921059. pii: .

Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT.

Bone marrow transplantation. 2026 Feb; 61(Feb):149-158. doi: 10.1038/s41409-025-02740-w. pii: .

Primary Cutaneous B-Cell Lymphomas: An Updated Portrait of Classification, Biology, and Clinical Management.

European journal of haematology. 2026 Feb; 116(Feb):116-128. doi: 10.1111/ejh.70053. pii: .

Novel and experimental anticoagulant strategies beyond current direct oral anticoagulants.

Journal of thrombosis and haemostasis : JTH. 2026 Jan; doi: 10.1016/j.jtha.2025.11.033. pii: S1538-7836(25)00919-5.

Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.

Blood advances. 2026 Jan; doi: 10.1182/bloodadvances.2025018152. pii: bloodadvances.2025018152.

New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.

Blood advances. 2026 Jan; 10(Jan):217-227. doi: 10.1182/bloodadvances.2024015599. pii: .

Beyond Expansion: Tumor Debulking as Key to Improving CAR T-Cell Potential in Lymphoma.

Blood cancer discovery. 2026 Jan; 7(Jan):11-14. doi: 10.1158/2643-3230.BCD-25-0397. pii: .

When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma?

Hematology. American Society of Hematology. Education Program. 2025 Dec; 2025(Dec):564-570. doi: 10.1182/hematology.2025000750. pii: .

An updated understanding of follicular lymphoma transformation.

Blood. 2025 Oct; 146(Oct):1812-1823. doi: 10.1182/blood.2024026016. pii: .

A clinical guide to TP53 mutations in myeloid neoplasms.

Blood. 2025 Oct; 146(Oct):2157-2167. doi: 10.1182/blood.2025029691. pii: .

Emerging therapeutic strategies for mature T-cell and natural killer-cell lymphomas.

The Lancet. Haematology. 2025 Oct; 12(Oct):e823-e835. doi: 10.1016/S2352-3026(25)00228-5. pii: S2352-3026(25)00228-5.

Antithrombotic Therapy in People with Hemophilia-A Narrative Review.

Thrombosis and haemostasis. 2025 Nov; 125(Nov):1060-1068. doi: 10.1055/a-2548-4192. pii: .

Understanding and Managing Infectious Complications in Chronic Lymphocytic Leukemia.

Hematology/oncology clinics of North America. 2025 Oct; 39(Oct):1031-1056. doi: 10.1016/j.hoc.2025.05.003. pii: S0889-8588(25)00065-6.

Triplet Therapies in Chronic Lymphocytic Leukemia.

Hematology/oncology clinics of North America. 2025 Oct; 39(Oct):903-915. doi: 10.1016/j.hoc.2025.05.001. pii: S0889-8588(25)00063-2.

Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report.

American journal of hematology. 2025 Oct; 100(Oct):1813-1827. doi: 10.1002/ajh.70011. pii: .

Monoclonal Gammopathy of Undetermined Significance.

The New England journal of medicine. 2025 Oct; 393(Oct):1315-1326. doi: 10.1056/NEJMra2412716. pii: .

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

The New England journal of medicine. 2025 Sep; 393(Sep):1177-1190. doi: 10.1056/NEJMoa2504341. pii: .

Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia.

The New England journal of medicine. 2025 Sep; 393(Sep):879-886. doi: 10.1056/NEJMoa2507175. pii: .

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis.

Blood. 2025 Aug; 146(Aug):1011-1029. doi: 10.1182/blood.2024027197. pii: .

Direct Oral Anticoagulants: Quick Primer on When to Use and When to Avoid.

Thrombosis and haemostasis. 2025 Jul; 125(Jul):611-617. doi: 10.1055/a-2451-4014. pii: .

Consensus on the Management of the Clinical Challenges of Venous Thromboembolism in Special Situations.

Thrombosis and haemostasis. 2025 Oct; 125(Oct):944-959. doi: 10.1055/a-2595-1811. pii: .

Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies.

Transplantation and cellular therapy. 2024 Oct; 30(Oct):955-969. doi: 10.1016/j.jtct.2024.07.018. pii: S2666-6367(24)00549-9.

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.

Blood. 2025 Jul; 146(Jul):291-303. doi: 10.1182/blood.2024028064. pii: .

JSH practical guidelines for hematological malignancies, 2023 III. Myeloma 2. Related disorders of multiple myeloma.

International journal of hematology. 2025 Oct; 122(Oct):510-520. doi: 10.1007/s12185-025-04051-8. pii: .

JSH practical guidelines for hematological malignancies, 2023 III. Myeloma 1. Multiple myeloma (MM).

International journal of hematology. 2025 Oct; 122(Oct):465-509. doi: 10.1007/s12185-025-04045-6. pii: .

2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura.

Journal of thrombosis and haemostasis : JTH. 2025 Nov; 23(Nov):3711-3732. doi: 10.1016/j.jtha.2025.06.002. pii: S1538-7836(25)00360-5.

Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.

American journal of hematology. 2025 May; 100(May):860-891. doi: 10.1002/ajh.27625. pii: .

International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology.

Journal of thrombosis and haemostasis : JTH. 2024 Sep; 22(Sep):2629-2652. doi: 10.1016/j.jtha.2024.05.026. pii: S1538-7836(24)00318-0.

A British Society for Haematology guideline on the assessment and management of bleeding risk prior to invasive procedures.

British journal of haematology. 2024 May; 204(May):1697-1713. doi: 10.1111/bjh.19360. pii: .

Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline.

British journal of haematology. 2024 Jan; doi: 10.1111/bjh.19236. pii: .

Diagnosis and management of heparin-induced thrombocytopenia: Third edition.

British journal of haematology. 2024 Feb; 204(Feb):459-475. doi: 10.1111/bjh.19180. pii: .

Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.

British journal of haematology. 2024 Feb; doi: 10.1111/bjh.19333. pii: .

Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN. 2024 Oct; 22(Oct):563-576. doi: 10.6004/jnccn.2024.0051. pii: .

Expert consensus guidelines: Intravenous iron uses, formulations, administration, and management of reactions.

American journal of hematology. 2024 Jan; doi: 10.1002/ajh.27220. pii: .

Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage.

JAMA. 2016 Nov; 316(Nov):2025-2035. doi: 10.1001/jama.2016.9185. pii: .

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

The New England journal of medicine. 2026 Feb; 394(Feb):739-752. doi: 10.1056/NEJMoa2514663. pii: .

Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard?

Oncology (Williston Park, N.Y.). 2026 Feb; 40(Feb):34-42. doi: 10.46883/2026.25921059. pii: .

Primary Cutaneous B-Cell Lymphomas: An Updated Portrait of Classification, Biology, and Clinical Management.

European journal of haematology. 2026 Feb; 116(Feb):116-128. doi: 10.1111/ejh.70053. pii: .

Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT.

Bone marrow transplantation. 2026 Feb; 61(Feb):149-158. doi: 10.1038/s41409-025-02740-w. pii: .

Efficacy of CD19 CAR T-cell therapy for patients with B-cell acute lymphoblastic leukemia relapsed after allogeneic transplantation.

Leukemia & lymphoma. 2026 Jan; 1-4. doi: 10.1080/10428194.2026.2619496. pii: .

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.

Blood advances. 2026 Jan; 10(Jan):228-232. doi: 10.1182/bloodadvances.2025016968. pii: .

Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.

Blood advances. 2026 Jan; doi: 10.1182/bloodadvances.2025018152. pii: bloodadvances.2025018152.

New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.

Blood advances. 2026 Jan; 10(Jan):217-227. doi: 10.1182/bloodadvances.2024015599. pii: .

Beyond Expansion: Tumor Debulking as Key to Improving CAR T-Cell Potential in Lymphoma.

Blood cancer discovery. 2026 Jan; 7(Jan):11-14. doi: 10.1158/2643-3230.BCD-25-0397. pii: .

Novel and experimental anticoagulant strategies beyond current direct oral anticoagulants.

Journal of thrombosis and haemostasis : JTH. 2026 Jan; doi: 10.1016/j.jtha.2025.11.033. pii: S1538-7836(25)00919-5.